Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

An animal model of MYC-driven medulloblastoma.

Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, Northcott PA, Taylor MD, Pfister SM, Febbo PG, Wechsler-Reya RJ.

Cancer Cell. 2012 Feb 14;21(2):155-67. doi: 10.1016/j.ccr.2011.12.021.

2.

Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.

Metcalfe C, de Sauvage FJ.

Cancer Res. 2011 Aug 1;71(15):5057-61. doi: 10.1158/0008-5472.CAN-11-0923. Epub 2011 Jul 19. Review. Erratum in: Cancer Res. 2011 Sep 15;71(18):6087.

3.

Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.

Dijkgraaf GJ, Alicke B, Weinmann L, Januario T, West K, Modrusan Z, Burdick D, Goldsmith R, Robarge K, Sutherlin D, Scales SJ, Gould SE, Yauch RL, de Sauvage FJ.

Cancer Res. 2011 Jan 15;71(2):435-44. doi: 10.1158/0008-5472.CAN-10-2876. Epub 2010 Dec 1.

4.

Regulation of cell cycle genes and induction of senescence by overexpression of OTX2 in medulloblastoma cell lines.

Bunt J, de Haas TG, Hasselt NE, Zwijnenburg DA, Koster J, Versteeg R, Kool M.

Mol Cancer Res. 2010 Oct;8(10):1344-57. doi: 10.1158/1541-7786.MCR-09-0546. Epub 2010 Sep 13.

5.

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira SM, García-Echeverría C, Briggs KJ, Watkins DN, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M.

Sci Transl Med. 2010 Sep 29;2(51):51ra70. doi: 10.1126/scitranslmed.3001599.

6.

Medulloblastoma comprises four distinct molecular variants.

Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD.

J Clin Oncol. 2011 Apr 10;29(11):1408-14. doi: 10.1200/JCO.2009.27.4324. Epub 2010 Sep 7.

7.

OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas.

Adamson DC, Shi Q, Wortham M, Northcott PA, Di C, Duncan CG, Li J, McLendon RE, Bigner DD, Taylor MD, Yan H.

Cancer Res. 2010 Jan 1;70(1):181-91. doi: 10.1158/0008-5472.CAN-09-2331. Epub 2009 Dec 22.

8.
9.

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ.

Science. 2009 Oct 23;326(5952):572-4. doi: 10.1126/science.1179386. Epub 2009 Sep 2.

10.

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.

Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA.

N Engl J Med. 2009 Sep 17;361(12):1173-8. doi: 10.1056/NEJMoa0902903. Epub 2009 Sep 2.

11.

Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).

Tremblay MR, Lescarbeau A, Grogan MJ, Tan E, Lin G, Austad BC, Yu LC, Behnke ML, Nair SJ, Hagel M, White K, Conley J, Manna JD, Alvarez-Diez TM, Hoyt J, Woodward CN, Sydor JR, Pink M, MacDougall J, Campbell MJ, Cushing J, Ferguson J, Curtis MS, McGovern K, Read MA, Palombella VJ, Adams J, Castro AC.

J Med Chem. 2009 Jul 23;52(14):4400-18. doi: 10.1021/jm900305z.

PMID:
19522463
12.

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA.

Science. 2009 Jun 12;324(5933):1457-61. doi: 10.1126/science.1171362. Epub 2009 May 21.

13.

Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells.

Yang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourboulas M, Schüller U, Machold R, Fishell G, Rowitch DH, Wainwright BJ, Wechsler-Reya RJ.

Cancer Cell. 2008 Aug 12;14(2):135-45. doi: 10.1016/j.ccr.2008.07.003.

14.

Medulloblastoma: from molecular pathology to therapy.

Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A.

Clin Cancer Res. 2008 Feb 15;14(4):971-6. doi: 10.1158/1078-0432.CCR-07-2072. Review.

15.

Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci.

Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, Ravanpay AC, Stroud MR, Kusuma Y, Hansen SJ, Kwok D, Munoz NM, Sze RW, Grady WM, Greenberg NM, Ellenbogen RG, Olson JM.

Cancer Res. 2007 Jul 15;67(14):6882-8.

16.

Patched1 functions as a gatekeeper by promoting cell cycle progression.

Adolphe C, Hetherington R, Ellis T, Wainwright B.

Cancer Res. 2006 Feb 15;66(4):2081-8.

17.

Drug resistance in brain diseases and the role of drug efflux transporters.

Löscher W, Potschka H.

Nat Rev Neurosci. 2005 Aug;6(8):591-602. Review.

PMID:
16025095
18.

Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid.

Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, Lengauer C, Cummins JM, Velculescu VE, Fults DW, McLendon RE, Bigner DD, Yan H.

Cancer Res. 2005 Feb 1;65(3):919-24.

19.

Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice.

Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, Connelly M, Stewart CF, Gould S, Rubin LL, Curran T.

Cancer Cell. 2004 Sep;6(3):229-40.

20.

Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened.

Chen JK, Taipale J, Cooper MK, Beachy PA.

Genes Dev. 2002 Nov 1;16(21):2743-8.

Supplemental Content

Support Center